CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Ivabradine (Procoralan) +1 moredrug
Likely dose
Ivabradine (Procoralan) 7,5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01365286
NCT01365286Phase 4Completed
CompareCT.gov

Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease

Medical University of Lodz·interventional·Posted Jun 3, 2011·Updated Jun 12, 2012

In Brief

A Phase 4 clinical trial evaluating Ivabradine (Procoralan) and Placebo for Asthma, Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate heart rate lowering efficacy and respiratory safety of ivabradine in patients with asthma and COPD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Chronic Obstructive Pulmonary Disease (COPD)
CountriesPoland
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 3, 2011
Enrollment StartMay 1, 2009
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.1 years ago

Interventions

Ivabradine (Procoralan)drug

Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)

Placebodrug

Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)